Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
SMBC Nikko Initiates Coverage On Nkarta with Outperform Rating, Announces Price Target of $50
SMBC Nikko analyst David Dai initiates coverage on Nkarta (NASDAQ:NKTX) with a Outperform rating and announces Price Target of $50.
Nkarta Q3 EPS $(0.68) Up From $(6.08) YoY
Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.68) per share. This is a 88.82 percent increase over losses of $(6.08) per share from the same period last year.
MaxCyte Reports Strategic Platform License With Nkarta to Advance Natural Killer Cell Therapy Programs
MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT, MXCN)), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic platform license (SPL) with Nkarta, Inc., a
Nkarta Expects Initial Data From CAR NK Cell Therapy In Blood Cancer In 2022
Nkarta Inc (NASDAQ:NKTX) has updated guidance on initial data readout of Phase 1 trial of NKX101 in relapsed or refractory acute…
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
53 Biggest Movers From Friday
Gainers
Innate Pharma S.A. (NASDAQ: IPHA) shares surged 47.1% to settle at $6.15 on Friday after SVB Leerink upgraded the stock from Market Perform to Outperform.